E-resources
PDF-
Perez, Elena E., MD, PhD; Orange, Jordan S., MD, PhD; Bonilla, Francisco, MD, PhD; Chinen, Javier, MD, PhD; Chinn, Ivan K., MD; Dorsey, Morna, MD, MMSc; El-Gamal, Yehia, MD, PhD; Harville, Terry O., MD, PhD; Hossny, Elham, MD, PhD; Mazer, Bruce, MD; Nelson, Robert, MD; Secord, Elizabeth, MD, PhD; Jordan, Stanley C., MD; Stiehm, E. Richard, MD; Vo, Ashley A., PharmD; Ballow, Mark, MD
Journal of allergy and clinical immunology, 03/2017, Volume: 139, Issue: 3Journal Article
Human immunoglobulin preparations for intravenous or subcutaneous administration are the cornerstone of treatment in patients with primary immunodeficiency diseases affecting the humoral immune system. Intravenous preparations have a number of important uses in the treatment of other diseases in humans as well, some for which acceptable treatment alternatives do not exist. We provide an update of the evidence-based guideline on immunoglobulin therapy, last published in 2006. Given the potential risks and inherent scarcity of human immunoglobulin, careful consideration of its indications and administration is warranted.
